MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202511122581 A) filed by Bioinformatics Project And Research Institute; and Dr Uma Kumari, Noida, Uttar Pradesh, on Dec. 5, 2025, for 'integrative crispr-cas9 and gwas approach to functionally evaluate alk resistance mutations in blood malignancies.'
Inventor(s) include Dr Uma Kumari; Tanmay Tanaji Bandbe; and Vineeta Johri.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "The present invention provides a comprehensive method for functional validation of ALK gene variants identified through genome-wide association studies using CRISPR-Cas9 genome editing technology. The method integrates structural bioinformatics analysis from databases including PDB, MMDB, UniProt, and COSMIC 3D with computational tools such as E-CRISPR and CHOPCHOP for precise guide RNA design. The invention enables identification and experimental validation of resistance-conferring mutations in ALK-positive cancers, particularly those resistant to tyrosine kinase inhibitors. By combining computational modeling with experimental genome editing in ALK-dependent cell lines, the method allows accurate classification of variants as resistance-conferring, neutral, or uncertain. The validated variants are analyzed through proliferation assays, drug-response testing, and signal transduction studies. This integrative approach bridges the gap between variant identification and clinical interpretation, providing actionable information for personalized cancer therapy and next-generation inhibitor design."
Disclaimer: Curated by HT Syndication.
